The purpose of this review is to provide a comprehensive overview of the main promising therapeutic targets beyond EGFR, ALK, ROS1 and BRAF and to discuss their potential implications in reshaping the current treatment algorithm for stage advanced NSCLC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.